Phyton Biotech announces acquisition of Controlled Substances Dealers License from Health Canada


Phyton Biotech announces acquisition of Controlled Substances Dealers License from Health Canada

Delta, British Columbia, November 29, 2023 – Phyton Biotech LLC. proudly announces a significant milestone in its journey toward advancing pharmaceutical research and development. The Company is pleased to announce the receipt of its Controlled Substances Dealers License (CSDL) from Health Canada, effective November 2023. This pivotal license empowers Phyton Biotech to engage in groundbreaking work with psilocin and psilocybin.

Backed by over two decades of expertise in purifying and isolating natural active pharmaceuticals within a Good Manufacturing Practice (GMP) environment, Phyton Biotech recognizes the growing need to support companies exploring clinically important drugs in this space. As a testament to its commitment to innovation and collaboration, Phyton Biotech is ready to serve the psilocin and psilocybin market as a Contract Development and Manufacturing Organization (CDMO). This work will be undertaken by Phyton’s second GMP manufacturing facility conveniently located near Vancouver, Canada.

“This milestone marks a new chapter for Phyton Biotech as we enter the evolving landscape of psilocin and psilocybin research. With our Controlled Substances Dealers License, we are well-positioned to contribute to the development of clinically significant drugs,” said Colin Marr, President at Phyton Biotech.

Phyton Biotech aims to extend its specialized services to other licensed companies, providing them with scaled purification expertise, process optimization, chemistry, and quality assurance. As a trusted partner, Phyton understands the importance of delivering pharmaceutical solutions that meet the highest standards for safety, quality, and efficacy.

Phyton Biotech’s CDMO services encompass a comprehensive range of capabilities, including but not limited to:

  • Scaled Purification Expertise: Leveraging its extensive experience, Phyton provides advanced purification techniques tailored to meet the unique requirements of psilocin and psilocybin.
  • Chemistry: Phyton’s team of experts is dedicated to advancing the chemistry behind these compounds, ensuring precision and innovation in the drug development process.
  • Process Optimization: Help clients find the optimal process to support future commercial scale manufacturing.
  • Quality Assurance: Committed to the highest standards for quality, Phyton’s Quality Assurance team diligently oversees every stage of the development and manufacturing process to guarantee the safety and efficacy of the end product.
  • Phyton Biotech invites interested parties to explore collaborative opportunities in the pursuit of advancing pharmaceutical research and bringing novel therapies to market.

For inquiries and partnership opportunities, please contact:

Stephen Ball
VP of Business Development
[email protected]

About Phyton Biotech LLC.

Phyton Biotech LLC. is a leading provider of specialized services in the purification and isolation of natural active pharmaceuticals. With a rich history spanning over two decades, Phyton Biotech is dedicated to supporting advancements in pharmaceutical research and development. The recent acquisition of the Controlled Substances Dealers License underscores Phyton Biotech’s commitment to exploring new frontiers in drug development, particularly in the emerging field of psilocin and psilocybin. Learn more at

To download a copy of this press release, click here.